Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.

Edward M VitalJoan T MerrillEric F MorandRichard A FurieIan N BruceYoshiya TanakaSusan ManziKenneth C KalunianRubana N KalyaniKatie StreicherGabriel AbreuRaj Tummala

Published in: Annals of the rheumatic diseases (2022)

NCT02446912, NCT02446899.

Keyphrases

phase iii
open label
clinical trial
systemic lupus erythematosus
double blind
phase ii
placebo controlled
electronic health record
genome wide
copy number
big data
disease activity
genome wide identification
artificial intelligence
machine learning